ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO400

Renoprotective Function of Liver Type Fatty Acid Binding Protein (L-FABP) in Diabetic Kidney Disease via Activation of Mitochondrial Function

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Watanabe, Shiika, St. Marianna University School of Medicine, Kawasaki, Japan
  • Sugaya, Takeshi, St. Marianna University School of Medicine, Kawasaki, Japan
  • Ichikawa, Daisuke, St. Marianna University School of Medicine, Kawasaki, Japan
  • Kimura, Kenjiro, Tokyo Takanawa Hospital, Tokyo, Japan
  • Shibagaki, Yugo, St. Marianna University School of Medicine, Kawasaki, Japan
  • Ikemori, Atsuko, St. Marianna University School of Medicine, Kawasaki, Japan
Background


Tubulointerstitial damage (TID) in diabetic kidney disease (DKD) is one feature of histopathology observed in the diabetic patients with early progressive renal decline. Therefore, TID is a therapeutic target in order to prevent the progression of DKD. Recently, TID in DKD is reported to be associated with renal mitochondrial injury. Renal liver type fatty acid binding protein (L-FABP) has an anti-oxidant effect as a scavenger of reactive oxygen species. However, the interaction between renal L-FABP and mitochondrial function has not been investigated yet. Therefore, the aim of this study is to reveal the renoprotective potential of renal L-FABP via activation of mitochondrial function in streptozotocin-induced DKD.

Methods



To evaluate the role of renal L-FABP, we used human L-FABP chromosomal transgenic (Tg) mice because L-FABP is not expressed in the kidneys of wild-type (WT) mice.
The (Tg) mice and wild-type (WT) mice were divided into two groups: diabetic mice were injected with STZ; control mice were injected with a citrate buffer alone. At 19 weeks after these injections, the mice were killed and the kidney, and urine were isolated for analysis.

Results


The expression of renal L-FABP and the level of urinary L-FABP increased significantly in diabetic Tg mice compared to control Tg mice. Urinary albumin levels, the expression of α-smooth muscle actin in the interstitium and the level of renal oxidative protein were significantly lower in diabetic Tg kidneys compared with diabetic WT kidneys. The expression of mitochondrial superoxide dismutase 2 was significantly higher in diabetic Tg kidneys compared with diabetic WT kidneys. In the diabetic Tg kidneys, the expression of PPARγ co-activator 1α(PGC-1α ) was significantly higher than that of diabetic WT kidneys.

Conclusion


In conclusion, renal L-FABP could activate mitochondrial function by acceleration of mitochondrial biogenesis due to rise of PGC-1α expression, and attenuate renal oxidative stress, and consequently, the renal fibrosis were prevented. Increase in renal L-FABP expression may be a promising treatment against TID in DKD.